UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Annals of the rheumatic diseases, 2022-01, Vol.81 (1), p.100-107

2022

Volltextzugriff (PDF)

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Arthritis & rheumatology (Hoboken, N.J.), 2012-04, Vol.64 (4), p.1215-1226

2012

Volltextzugriff (PDF)

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2017-05, Vol.69 (5), p.932-942

2017

Volltextzugriff (PDF)

Targeting Cell Death Pathways for Therapeutic Intervention in Kidney Diseases

Seminars in nephrology, 2016-05, Vol.36 (3), p.153-161

2016

Volltextzugriff (PDF)

Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial

Arthritis & rheumatology (Hoboken, N.J.), 2024-02, Vol.76 (2), p.247-254

2024

Volltextzugriff (PDF)

Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects

Clinical pharmacokinetics, 2017-07, Vol.56 (7), p.747-757

2017

Volltextzugriff (PDF)

The Effect of Verapamil, a P‐Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once‐Daily JAK Inhibitor

Clinical pharmacology in drug development, 2017-11, Vol.6 (6), p.548-555

2017

Volltextzugriff (PDF)

Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts

American journal of hypertension, 2005-05, Vol.18 (5), p.619-626

2005

Volltextzugriff (PDF)

Neuroscience Research using Small Animals on a Chip: From Nematodes to Zebrafish Larvae

BioChip Journal, 2021, 15(1), , pp.42-51

2021

Volltextzugriff (PDF)

Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease

Vascular medicine (London, England), 2002-02, Vol.7 (1), p.35-43

2002

Volltextzugriff (PDF)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

Rheumatology and therapy., 2019-12, Vol.6 (4), p.503-520

2019

Volltextzugriff (PDF)

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database

Clinical therapeutics, 2009-11, Vol.31 (11), p.2653-2664

2009

Volltextzugriff (PDF)

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients

Transplantation direct, 2023-02, Vol.9 (2), p.e1436-e1436

2023

Volltextzugriff (PDF)

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis

Clinical journal of the American Society of Nephrology, 2018-10, Vol.13 (10), p.1502-1509

2018

Volltextzugriff (PDF)

A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy

Clinical pharmacology in drug development, 2016-07, Vol.5 (4), p.259-268

2016

Volltextzugriff (PDF)

The expanding world of metabolic enzymes moonlighting as RNA binding proteins

Biophysical journal, 2022-02, Vol.121 (3), p.344a-345a

2022

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients

Clinical pharmacology in drug development, 2016-09, Vol.5 (5), p.408-425

2016

Volltextzugriff (PDF)

Kidney-Related Outcomes in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of the Phase 2 NOBILITY Trial: TH-OR30

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.9-9

2023

Volltextzugriff (PDF)

3280 B-CELL RECOVERY IN A RANDOMIZED CONTROLLED TRIAL OF B-CELL DEPLETION WITH OBINUTUZUMAB FOR THE TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS (NOBILITY)

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review

Hypertension (Dallas, Tex. 1979), 2006-08, Vol.48 (2), p.219-224

2006

Volltextzugriff (PDF)

Prediction of Histologic Class Using Deep Learning on Renal Biopsies from a Trial of Obinutuzumab for Proliferative Lupus Nephritis: PO1762

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.551-551

2020

Volltextzugriff (PDF)

Designing a public access naloxone program for public transportation stations

Healthcare : the journal of delivery science and innovation, 2023-06, Vol.11 (2), p.100694, Article 100694

2023

Volltextzugriff (PDF)

Machine-Learning-Quantified Lupus Nephritis Histological Features Correlate With NIH Activity and Chronicity Index Subscores: TH-PO567

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.208-208

2022

Volltextzugriff (PDF)

Two-Year Results from a Randomized, Controlled Study of Obinutu-zumab for Proliferative Lupus Nephritis: SU-OR31

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.53-53

2020

Volltextzugriff (PDF)

Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study

American journal of nephrology, 2005-07, Vol.25 (4), p.393-399

2005

Volltextzugriff (PDF)

1 – 25 von 313

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(282)
Mit Volltextzugriff
(264)

Publikationsform

Sprache

Englisch
(311)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(197)
Life Sciences & Biomedicine
(169)
Humans
(137)
Female
(99)
Male
(93)
Middle Aged
(72)
Adult
(64)
Aged
(59)
Risk Factors
(49)
Prospective Studies
(46)
Biological And Medical Sciences
(39)
Medical Sciences
(37)
Technology
(26)
Aged, 80 And Over
(25)
Urology & Nephrology
(25)
Carpal Tunnel Syndrome
(23)
Engineering
(22)
Ergonomics
(22)
Public, Environmental & Occupational Health
(22)
Young Adult
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

Targeting Cell Death Pathways for Therapeutic Intervention in Kidney Diseases

Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial

Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects

The Effect of Verapamil, a P‐Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once‐Daily JAK Inhibitor

Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts

Neuroscience Research using Small Animals on a Chip: From Nematodes to Zebrafish Larvae

Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis

A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy

The expanding world of metabolic enzymes moonlighting as RNA binding proteins

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients

Kidney-Related Outcomes in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of the Phase 2 NOBILITY Trial: TH-OR30

3280 B-CELL RECOVERY IN A RANDOMIZED CONTROLLED TRIAL OF B-CELL DEPLETION WITH OBINUTUZUMAB FOR THE TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS (NOBILITY)

Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review

Prediction of Histologic Class Using Deep Learning on Renal Biopsies from a Trial of Obinutuzumab for Proliferative Lupus Nephritis: PO1762

Designing a public access naloxone program for public transportation stations

Machine-Learning-Quantified Lupus Nephritis Histological Features Correlate With NIH Activity and Chronicity Index Subscores: TH-PO567

Two-Year Results from a Randomized, Controlled Study of Obinutu-zumab for Proliferative Lupus Nephritis: SU-OR31

Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study

Suchergebnisse filtern